0.83
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Curative Biotechnology
Its shares trade under the ticker CUBT. It has been listed since 11 July 2001. In the fiscal year to 31 December 2016, it reported revenue of $11,091 and a net loss of $17,400. At that date it held total assets of $65,909 and shareholders' equity of −$636,384.
Curative Biotechnology, Inc. engages in the provision of software solutions for the healthcare market. The company is headquartered in Boca Raton, Florida. The company went IPO on 2001-07-11. The firm is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. The company has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. The company is focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its pipeline products include IMT504, CURB906, Metformin Reformulation, and COVID Vaccine with IMT504 Adjuvant. IMT504 is an immunotherapy for late-stage symptomatic rabies. CURB906 is a humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 11 Jul 2001
- Employees
- 4
- Website
- curativebiotech.com ↗
- Head office
- 1825 NW CORPORATE BLVD, BOCA RATON, FL, 33431
- Incorporated in
- FL
- Classification
- Biological Products, (No Diagnostic Substances)
Leadership
Pay as last reported
- Mr. Paul MichaelsChairman of the Board, President, since 2020$783,110
- Mr. Richard GarrChief Executive Officer, Chief Financial Officer, General Counsel$438,000
- Dr. Theressa HeahIndependent Director
- Mr. Thomas PossIndependent Director
- Mr. Cary SucoffIndependent Director
- Mr. Lawrence ZaslowIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Curative Biotechnology Inc focuses on rare disease therapeutic drug candidates in degenerative eye disease, infectious disease, and neuro oncology.
- The company's pipeline includes IMT504 for rabies, CURB906 for cancer, and Metformin Reformulation for AMD treatment.
- Curative Biotechnology Inc employs 4 full-time staff with a focus on developing disease-modifying drugs for specific medical conditions.
Weaknesses
- The company has only 4 full-time employees which limits its operational capacity and development speed.
- Curative Biotechnology Inc's IPO in 2001 indicates a long-standing but small-scale operation with limited resources.
- The firm's focus on rare disease indications may restrict market size and revenue potential compared to broader therapeutic areas.
Opportunities
- The degenerative eye disease platform offers potential for expanding the Metformin Reformulation to treat intermediate and late-stage AMD.
- The ongoing programs in infectious disease and neuro oncology could lead to new therapeutic applications and partnerships.
- Curative Biotechnology Inc can leverage its pipeline products like IMT504 and CURB906 for future market entry in targeted disease areas.
Threats
- The rare disease focus may face challenges in securing sufficient funding due to smaller patient populations and market size.
- Competition in the biotechnology sector for rare disease treatments could intensify as more companies enter the space.
- Regulatory hurdles for drug development in neuro oncology and infectious disease may delay product approvals and market entry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.